Cargando…
Salivary gland cancer organoids are valid for preclinical genotype-oriented medical precision trials
Salivary gland cancers (SGCs) are heterogeneous tumors, and precision oncology represents a promising therapeutic approach; however, its impact on SGCs remains obscure. This study aimed to establish a translational model for testing molecular-targeted therapies by combining patient-derived organoids...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189274/ https://www.ncbi.nlm.nih.gov/pubmed/37207275 http://dx.doi.org/10.1016/j.isci.2023.106695 |
_version_ | 1785043052382912512 |
---|---|
author | Ishikawa, Tomohiko Ogawa, Takenori Shiihara, Masahiro Usubuchi, Hajime Omori, Yuko Hirose, Katsuya Itoh, Taito Yoshida, Takuya Nakanome, Ayako Okoshi, Akira Higashi, Kenjiro Ishii, Ryo Rokugo, Masahiro Wakamori, Shun Okamura, Yasunobu Kinoshita, Kengo Katori, Yukio Furukawa, Toru |
author_facet | Ishikawa, Tomohiko Ogawa, Takenori Shiihara, Masahiro Usubuchi, Hajime Omori, Yuko Hirose, Katsuya Itoh, Taito Yoshida, Takuya Nakanome, Ayako Okoshi, Akira Higashi, Kenjiro Ishii, Ryo Rokugo, Masahiro Wakamori, Shun Okamura, Yasunobu Kinoshita, Kengo Katori, Yukio Furukawa, Toru |
author_sort | Ishikawa, Tomohiko |
collection | PubMed |
description | Salivary gland cancers (SGCs) are heterogeneous tumors, and precision oncology represents a promising therapeutic approach; however, its impact on SGCs remains obscure. This study aimed to establish a translational model for testing molecular-targeted therapies by combining patient-derived organoids and genomic analyses of SGCs. We enrolled 29 patients, including 24 with SGCs and 5 with benign tumors. Resected tumors were subjected to organoid and monolayer cultures, as well as whole-exome sequencing. Organoid and monolayer cultures of SGCs were successfully established in 70.8% and 62.5% of cases, respectively. Organoids retained most histopathological and genetic profiles of their original tumors. In contrast, 40% of the monolayer-cultured cells did not harbor somatic mutations of their original tumors. The efficacy of molecular-targeted drugs tested on organoids depended on their oncogenic features. Organoids recapitulated the primary tumors and were useful for testing genotype-oriented molecular targeted therapy, which is valuable for precision medicine in patients with SGCs. |
format | Online Article Text |
id | pubmed-10189274 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-101892742023-05-18 Salivary gland cancer organoids are valid for preclinical genotype-oriented medical precision trials Ishikawa, Tomohiko Ogawa, Takenori Shiihara, Masahiro Usubuchi, Hajime Omori, Yuko Hirose, Katsuya Itoh, Taito Yoshida, Takuya Nakanome, Ayako Okoshi, Akira Higashi, Kenjiro Ishii, Ryo Rokugo, Masahiro Wakamori, Shun Okamura, Yasunobu Kinoshita, Kengo Katori, Yukio Furukawa, Toru iScience Article Salivary gland cancers (SGCs) are heterogeneous tumors, and precision oncology represents a promising therapeutic approach; however, its impact on SGCs remains obscure. This study aimed to establish a translational model for testing molecular-targeted therapies by combining patient-derived organoids and genomic analyses of SGCs. We enrolled 29 patients, including 24 with SGCs and 5 with benign tumors. Resected tumors were subjected to organoid and monolayer cultures, as well as whole-exome sequencing. Organoid and monolayer cultures of SGCs were successfully established in 70.8% and 62.5% of cases, respectively. Organoids retained most histopathological and genetic profiles of their original tumors. In contrast, 40% of the monolayer-cultured cells did not harbor somatic mutations of their original tumors. The efficacy of molecular-targeted drugs tested on organoids depended on their oncogenic features. Organoids recapitulated the primary tumors and were useful for testing genotype-oriented molecular targeted therapy, which is valuable for precision medicine in patients with SGCs. Elsevier 2023-04-20 /pmc/articles/PMC10189274/ /pubmed/37207275 http://dx.doi.org/10.1016/j.isci.2023.106695 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Ishikawa, Tomohiko Ogawa, Takenori Shiihara, Masahiro Usubuchi, Hajime Omori, Yuko Hirose, Katsuya Itoh, Taito Yoshida, Takuya Nakanome, Ayako Okoshi, Akira Higashi, Kenjiro Ishii, Ryo Rokugo, Masahiro Wakamori, Shun Okamura, Yasunobu Kinoshita, Kengo Katori, Yukio Furukawa, Toru Salivary gland cancer organoids are valid for preclinical genotype-oriented medical precision trials |
title | Salivary gland cancer organoids are valid for preclinical genotype-oriented medical precision trials |
title_full | Salivary gland cancer organoids are valid for preclinical genotype-oriented medical precision trials |
title_fullStr | Salivary gland cancer organoids are valid for preclinical genotype-oriented medical precision trials |
title_full_unstemmed | Salivary gland cancer organoids are valid for preclinical genotype-oriented medical precision trials |
title_short | Salivary gland cancer organoids are valid for preclinical genotype-oriented medical precision trials |
title_sort | salivary gland cancer organoids are valid for preclinical genotype-oriented medical precision trials |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189274/ https://www.ncbi.nlm.nih.gov/pubmed/37207275 http://dx.doi.org/10.1016/j.isci.2023.106695 |
work_keys_str_mv | AT ishikawatomohiko salivaryglandcancerorganoidsarevalidforpreclinicalgenotypeorientedmedicalprecisiontrials AT ogawatakenori salivaryglandcancerorganoidsarevalidforpreclinicalgenotypeorientedmedicalprecisiontrials AT shiiharamasahiro salivaryglandcancerorganoidsarevalidforpreclinicalgenotypeorientedmedicalprecisiontrials AT usubuchihajime salivaryglandcancerorganoidsarevalidforpreclinicalgenotypeorientedmedicalprecisiontrials AT omoriyuko salivaryglandcancerorganoidsarevalidforpreclinicalgenotypeorientedmedicalprecisiontrials AT hirosekatsuya salivaryglandcancerorganoidsarevalidforpreclinicalgenotypeorientedmedicalprecisiontrials AT itohtaito salivaryglandcancerorganoidsarevalidforpreclinicalgenotypeorientedmedicalprecisiontrials AT yoshidatakuya salivaryglandcancerorganoidsarevalidforpreclinicalgenotypeorientedmedicalprecisiontrials AT nakanomeayako salivaryglandcancerorganoidsarevalidforpreclinicalgenotypeorientedmedicalprecisiontrials AT okoshiakira salivaryglandcancerorganoidsarevalidforpreclinicalgenotypeorientedmedicalprecisiontrials AT higashikenjiro salivaryglandcancerorganoidsarevalidforpreclinicalgenotypeorientedmedicalprecisiontrials AT ishiiryo salivaryglandcancerorganoidsarevalidforpreclinicalgenotypeorientedmedicalprecisiontrials AT rokugomasahiro salivaryglandcancerorganoidsarevalidforpreclinicalgenotypeorientedmedicalprecisiontrials AT wakamorishun salivaryglandcancerorganoidsarevalidforpreclinicalgenotypeorientedmedicalprecisiontrials AT okamurayasunobu salivaryglandcancerorganoidsarevalidforpreclinicalgenotypeorientedmedicalprecisiontrials AT kinoshitakengo salivaryglandcancerorganoidsarevalidforpreclinicalgenotypeorientedmedicalprecisiontrials AT katoriyukio salivaryglandcancerorganoidsarevalidforpreclinicalgenotypeorientedmedicalprecisiontrials AT furukawatoru salivaryglandcancerorganoidsarevalidforpreclinicalgenotypeorientedmedicalprecisiontrials |